On August 3, 2026 Inocras Inc., a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to deliver curated insights, reported that it has raised $31 million in an oversubscribed Series B-3 financing.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The financing brings Inocras’s total funding to approximately $100 million and supports the company’s growth. Inocras plans to expand its whole-genome sequencing and proprietary bioinformatics platform in the United States, building on demonstrated clinical deployment across Asia. As whole-genome sequencing moves toward broader adoption in oncology, Inocras is positioned to build on years of experience translating complex whole-genome data into curated, clinically actionable insights.
The round included participation from new and existing financial investors as well as strategic investors NDS Corporation and Aimed Bio Inc. New investors included IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities, and Shinhan Securities. Existing investors DSC Investment, Dunamu & Partners and InterVest also participated.
Inocras has established a record of real-world clinical adoption across Asia, with its whole-genome sequencing solutions currently used by more than 100 cancer institutions and in thousands of patient cases. The company has also established a significant commercial presence in Hong Kong and is supporting approximately thirty hospitals in South Korea.
Through its proprietary bioinformatics and automated interpretation capabilities, Inocras supports precision oncology applications spanning comprehensive tumor profiling with CancerVision and molecular residual disease detection with MRDVision.Across both solutions, the company analyzes genomic alterations and complex biomarkers across the cancer genome and translates those findings into clinically relevant insights. Inocras will use the proceeds to build on this momentum by expanding its U.S. commercial and operational infrastructure.
"We have already seen meaningful adoption across cancer institutions in Asia, where our technology has been used in thousands of patient cases," said Jehee Suh, CEO of Inocras. "Our next objective is to bring that clinical experience to the United States and help make whole-genome analysis a standard part of cancer care. This financing gives us the resources to expand our clinical presence, support adoption within hospitals, and build the evidence and infrastructure required to achieve that goal."
The financing follows continued clinical and scientific validation of Inocras’s whole-genome approach. Through its collaboration with researchers at the Broad Institute, Inocras recently analyzed whole-genome data from The Cancer Genome Atlas across thousands of cancer cases, demonstrating the utility of standardized whole-genome analysis at scale and informing broader use of comprehensive genomic information in oncology.
(Press release, Inocras, AUG 3, 2026, View Source [SID1234669625])